Hypermethylation of other genes such as CDH13 and FLBN3 is associated with poor prognosis in CRC [11] and some pharmacological compounds such as DNMT and histone deacetylase (HDAC) inhibitors are being tested in metastatic CRC patients to improve their survival or quality of life [12]. This evidence concerns the gene CDH13 and colorectal carcinoma.